NCT02791594

Imaging FDG Flare in Melanoma

Imaging the Flare Response With FDG PET/CT in Patients With Advanced Metastatic Melanoma on Pembrolizumab.

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 21 (actual)
• Sponsor: Abramson Cancer Center at Penn Medicine · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Up to 35 adult patients with metastatic melanoma planning to start pembrolizumab will be enrolled in this study with a target enrollment of 30 evaluable subjects. Subjects will complete a baseline FDG PET/CT and an on-treatment FDG PET/CT after 1 week of pembrolizumab therapy. Subjects may also be a part of the Penn Melanoma Tissue Collection Program and then will be asked to have one additional tumor biopsy and one additional blood draw for the purposes of this imaging study. Changes in tumor FDG uptake between the baseline and early on-treatment FDG PET/CT scans will be correlated with blood and tissue results from the patient's medical records and from the data collected as part of the Penn Melanoma Tissue Collection Program and with outcomes including objective response, progression free survival, and overall survival.

Conditions

• Metastatic Melanoma

Interventions

Type	Name	Description
DRUG	Pembrolizumab	Patients were treated with pembrolizumab according to standard of care.

Timeline

• Start date: 2016-06-01
• Primary completion: 2020-07-01
• Completion: 2020-07-01
• First posted: 2016-06-07
• Last updated: 2024-11-08
• Results posted: 2024-11-08

Locations

1 site across 1 country: United States